Orchid Pharma (LUX:ORCHP) Construction In Progress: $36.69 Mil (As of Mar. 2026)


LUX:ORCHP Orchid Pharma Ltd LUX:ORCHP
60 GF Score
Price $5.45
GF Value $4.60
! 10 Warning Signs
View Full Analysis

What is Orchid Pharma Construction In Progress?

Orchid Pharma LUX:ORCHP 60 Construction In Progress is $36.69 Mil as of Mar. 2026. GuruFocus rates LUX:ORCHP with a GF Score™ of 60/100 and a GF Value™ of $4.60. The stock has 10 warning signs investors should review.

Orchid Pharma's quarterly construction in progress declined from Sep. 2025 ($13.62 Mil) to Dec. 2025 ($0.00 Mil) but then increased from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($36.69 Mil).

Orchid Pharma's annual construction in progress increased from Mar. 2024 ($3.07 Mil) to Mar. 2025 ($14.60 Mil) and increased from Mar. 2025 ($14.60 Mil) to Mar. 2026 ($36.69 Mil).

Orchid Pharma Construction In Progress Historical Data

* Premium members only.

The historical data trend for Orchid Pharma's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orchid Pharma Construction In Progress Chart

Orchid Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.82 5.89 3.07 14.60 36.69

Orchid Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.60 0.00 13.62 0.00 36.69
LUX:ORCHP
60GF Score
Orchid Pharma Ltd LUX:ORCHP
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orchid Pharma Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of $36.69 Mil mean?
Orchid Pharma (LUX:ORCHP) has a Construction In Progress of $36.69 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Orchid Pharma and its competitors.
Is Orchid Pharma's Construction In Progress too high?
Orchid Pharma's current Construction In Progress is $36.69 Mil. Overall, Orchid Pharma has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Orchid Pharma's Construction In Progress compare to ZTS?
Orchid Pharma's Construction In Progress of $36.69 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Orchid Pharma and its competitors. Orchid Pharma's current Construction In Progress is $36.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orchid Pharma stock overvalued right now?
Orchid Pharma (LUX:ORCHP) has a current Construction In Progress of $36.69 Mil. The stock's GF Value™ is $4.60, compared to a current price of $5.45 — trading 18.5% above its estimated fair value. The current Construction In Progress is $36.69 Mil. Orchid Pharma's overall GF Score™ is 60/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Orchid Pharma (LUX:ORCHP), the current Construction In Progress is $36.69 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orchid Pharma (LUX:ORCHP) Overvalued in 2026?

Based on GuruFocus' analysis, Orchid Pharma stock appears to be overvalued. The current stock price of $5.45 is trading 18.5% above its estimated GF Value™ of $4.60.

Key valuation signals for LUX:ORCHP:

  • Construction In Progress: $36.69 Mil
  • GF Value™: $4.60 vs. price of $5.45 (18.5% above fair value)
  • GF Score™: 60/100 with 10 warning signs

No single metric tells the full story. See the LUX:ORCHP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orchid Pharma Business Description

Address Sector 74A, 15th Floor, Tower-1, DLF Corporate Greens, Narsinghpur, Gurugram, HR, IND, 122004
Orchid Pharma Ltd is involved in the development, manufacturing, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company operates in one business segment, which is Pharmaceuticals, in which the company derives its maximum sales through Active Pharmaceutical Ingredients. It produces various products such as tablets, injectables, and APIs for cardiovascular, anti-diabetic, neuropsychiatry, veterinary, non-antibiotic, and cephalosporins. The products are grouped under formulations and active pharmaceutical ingredients. Geographically, the company generates maximum revenue from the export of its products to international markets like the United States, Canada, Europe, Japan, Australia, and China etc., and the rest from its business in India.
60GF Score

Get the complete analysis for LUX:ORCHP

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.45
Price
$4.60
GF Value